Komodo Health cut Alnylam's reporting from months to hours. Now every new hire must pass an AI standard no other pharma firm requires.

The Alnylam Deal Deepens

On June 25, 2026, Komodo Health expanded its partnership with Alnylam Pharmaceuticals, the leading RNA interference therapeutics company, to push its Marmot analytics platform across Alnylam's customer-facing organization and into broader enterprise functions. The deal moves a pilot that began at launch into production at scale, and it says as much about where real-world evidence is heading in drug development as it does about either company.

Alnylam adopted Marmot after the platform launched in August 2025, starting with custom AI agents built for its commercial business. The expanded agreement extends that work into a unified intelligence layer spanning the customer-facing side of the organization, replacing fragmented dashboards and static reporting with real-time, reproducible analytics. Komodo CEO Arif Nathoo framed it bluntly: "We're moving from a world where every team operates from its own reports and analyses to one where an entire enterprise sees the same reality in real time and can act on it."

Marmot runs on Komodo's Healthcare Map, which covers more than 330 million de-identified patient journeys, a dataset that lets Alnylam's teams query real-world treatment patterns, prescriber behavior, and patient trajectories without stitching together separate data contracts. Komodo says Alnylam has already integrated a wide range of enterprise datasets into the platform and cut reporting cycles from months to hours. Tolga Tanguler, Alnylam's chief commercial officer, said the capability "strengthens our ability to connect insight into action, helping us scale more effectively, accelerate decision-making, and continue delivering sustainable growth while maintaining our focus on patients."

For RNAi specifically, the stakes are concrete. RNA interference drugs target disease at the mRNA level, which means their commercial and clinical success depends on identifying narrow patient populations, tracking specialist prescriber networks, and monitoring long-term real-world outcomes — exactly the kind of work that breaks traditional analytics workflows. Marmot lets users describe a patient population in plain language and get a full dashboard in minutes, without technical setup. That speed matters as Alnylam expands its portfolio beyond rare disease into larger therapeutic areas.

The deal also signals something about Komodo's own trajectory. The company released a set of new Marmot capabilities alongside the Alnylam announcement, including tools for reproducibility, auditability, and direct integration with existing enterprise systems, aimed at moving customers past pilot projects and into embedded, workflow-level AI. Amit Sangani, Komodo's CTO, said the organizations getting the most value from AI are the ones "embedding trusted intelligence directly into the workflows that drive critical decisions."

Miles Ennis as President — The Leadership Signal

Komodo Health elevated Miles Ennis to president in June 2026, a move that restructured the company's executive ladder. Co-founder Web Sun stepped into the co-CEO role alongside co-founder and CEO Arif Nathoo, while Ennis took over global go-to-market, operations, product strategy alignment, and marketing. The message was clear: Komodo is shifting from founder-led growth to operator-led scale.

Ennis joined Komodo as chief revenue officer in July 2024 and spent his first year proving the commercial model worked. He led the revenue organization past its targets and struck a partnership with Nasdaq that pushed Komodo's Healthcare Map into financial services, meaning hedge funds, private equity, and venture capital firms now use the same patient dataset that life sciences teams rely on. That cross-industry deal marked the first time Komodo's intelligence left healthcare, and it came from Ennis's team.

"Miles's impact has been profound and immediate," Web Sun said in announcing the COO promotion the previous September. By the time the president title arrived nine months later, the rationale was explicit: Komodo needed someone to align product engineering with customer demand as Marmot deployment accelerated across enterprise accounts.

Ennis brought more than twenty years at Talkdesk, IBM, Cisco, and Aspen Technology, running global teams through digital-transformation cycles, the resume of someone who has scaled revenue operations past the point where founder intuition stops being enough.

The leadership evolution tracks what Komodo's customers are doing. Healthcare and life sciences organizations are moving past AI pilots into enterprise-wide adoption. Teams that want healthcare-native AI at scale need a vendor that can deliver it operationally, not just technically. Putting a president in place signals Komodo intends to be that vendor.

What the role actually covers tells you where the company sees friction. Ennis owns commercial operations, product strategy alignment, and marketing, the three functions that tend to drift apart when a platform company grows fast. Product builds features the market hasn't asked for. Sales promises capabilities that don't ship. Marketing describes a company that operations can't support yet. Ennis's job is to close those gaps.

The parallel hire of Paul Thomas as CFO in April 2026 rounds out the picture. Komodo installed a president to run the machine and a CFO to fund the next phase, a leadership team built for a company that expects to get bigger, not one optimizing for an exit.

How Marmot Actually Works

The Alnylam expansion didn't happen on a slide deck. It runs on Marmot, Komodo Health's healthcare-native AI engine that launched in August 2025 and now functions as the infrastructure layer for the company's push into AI-native therapeutic intelligence. Understanding what Marmot does, and how it differs from slapping a chatbot on top of claims data, is the key to understanding why Komodo is hiring the way it is.

Marmot sits on top of Komodo's Healthcare Map, a knowledge graph built from the de-identified journeys of more than 330 million patients. The engine itself is what Komodo calls a "healthcare-native AI," a system designed specifically for pharmaceutical insights workflows rather than adapted from a general-purpose large language model. Arif Nathoo, Komodo's CEO and co-founder, said it "fundamentally enhances analytical velocity, transforming complex questions that previously took weeks to answer into strategic, evidence-based insights in minutes."

The architecture has three layers that matter for workforce implications. First, the reasoning layer: Marmot classifies incoming questions and routes each subtask to the appropriate model, rather than forcing every query through a single foundation model. Second, reproducibility: every step is versioned and saved, so the same analysis produces the same result next quarter. Third, an evaluation gate: outputs pass a benchmarking stage built for healthcare before delivery. Web Sun, Komodo's president and co-founder, said this addresses "the rigorous transparency and auditability standards that regulated industries require."

For technical teams, Komodo ships a Development Kit that puts the Healthcare Map directly into Snowflake, Databricks, or Python environments. Analysts can query cohorts, train ML models, and deploy custom AI agents without handoffs. The Alnylam enterprise agreement focuses on deploying these custom AI agents across commercial targeting, line-of-therapy analysis, patient journey mapping, and health-care resource-use pattern analysis.

The platform also includes Navigator, a natural-language interface that lets non-technical teams ask questions in plain English and get traceable answers. Taylor Woodroof, director of data analytics at Fairview Health Services, said: "When I saw what Marmot was capable of, I could not unsee it. It was like a fourth utensil. It could help us answer questions we had not even thought to ask, and it offered insights more quickly than a traditional approach." That dual audience, engineers building agents and commercial teams querying in plain language, is exactly why Komodo's hiring spans both AI engineering and consulting roles.

Marmot isn't a product Komodo sells. It's the system Komodo builds its workforce around.

Three Lists in One Day

On September 30, 2025, Komodo Health landed on three industry lists in a single day: the 2025 Forbes Cloud 100, TIME's inaugural World's Top HealthTech Companies, and The Healthcare Technology Report's Top 25 Healthcare Software Companies.

The Forbes Cloud 100 recognition carries the longest track record. This marks Komodo's fifth appearance on the list, which ranks the top 100 private cloud companies globally. Repeat placement signals sustained revenue growth and retention, not a single good quarter.

The TIME list, compiled with Statista, sorted companies on financial performance, reputation analysis, and online engagement. Komodo earned an "Outstanding" performance indicator in the AI & Data Analytics category, the highest-scoring category across the ranking, which TIME attributed to the broader boom in health-data-driven tools for screening, diagnostics, and patient matching.

The Healthcare Technology Report's list focused on software companies shaping healthcare delivery through analytics and AI. Komodo's placement there reinforces the same signal: industry analysts read the company as an infrastructure player, not a feature add-on.

Web Sun tied the three recognitions to the Marmot platform launch and the company's "full stack thesis" spanning the Healthcare Map, platform capabilities, and healthcare analytics AI. The timing matters: all three lists published within days of each other, and Komodo bundled them into a single narrative at the exact moment it was scaling the Alnylam partnership and hiring a new president. Awards don't build a workforce. But they lower the friction of convincing a senior engineer or data scientist to leave a brand-name company for a private one.

Who Komodo Is Hiring

Komodo's job postings read like a blueprint for the hybrid workforce Marmot demands. A recent Data Scientist III listing on Built In spells out the exact synthesis: three-plus years of Python and large-scale SQL, proficiency in PySpark and R, and direct experience with anonymized patient-level healthcare databases. Salary ranges for that role hit $161,000–$190,000 in San Francisco and New York, dropping to $140,000–$175,000 elsewhere.

The technical requirements are only half the equation. Komodo explicitly mandates an "AI Standard" for every hire, a reflexive expectation that new employees integrate large language models and AI assistants into daily tasks. The Data Scientist III posting requires candidates to "apply AI strategically," "use AI to accelerate feedback loops," and regularly use tools like Notion AI, Perplexity, Claude, and Microsoft Copilot. AI proficiency is a baseline condition of employment, not a nice-to-have.

Zero G Talent's board shows four roles added in the past seven days, including a Full-Stack AI Engineer and a Senior Manager, Field Systems & AI. Those two signals confirm the hiring axis: Komodo is staffing both the infrastructure layer that Marmot runs on and the field organization that deploys it to pharma clients. You don't pay top-of-band for a full-stack AI engineer to maintain status quo.

The workforce profile that emerges is bifurcated. On one side, deep technical operators who can build reproducible, auditable analytics pipelines over the Healthcare Map, people who can write PySpark against 330 million de-identified patient records and ship models that produce the same answer twice. On the other, client-facing consultants and field systems managers who can translate those outputs into therapeutic-area decisions at companies like Alnylam. The Data Scientist III posting asks for both: "strong business acumen" and the ability to "communicate complex data science topics to audiences of variable technical capability."

This mirrors the staffing pattern at other AI-native biotech companies, where ML engineers sit alongside former pharma scientists who can validate whether a model's output maps to biological reality. Komodo is chasing the same structure, except its domain is real-world evidence rather than wet-lab data. The risk is always the same: hire engineers who don't understand claims data and you get fast, wrong answers; hire healthcare analysts who can't code and you get slow, unscalable ones.

Is AI-Native Therapeutic Intelligence a Real Workforce Category?

The race to build an AI-native workforce in biopharma is not a single-company story. Komodo's expanded Alnylam partnership and its hiring surge sit inside a broader industry restructuring that is forcing incumbents and startups alike to rethink what a life sciences workforce even looks like.

The clearest signal came in March 2026, when IQVIA unveiled IQVIA.ai, a unified agentic AI platform built on NVIDIA's Nemotron and LangChain infrastructure. The platform deploys intelligent agents across clinical, commercial, and real-world evidence workflows, the same functional territory Komodo targets but from the opposite direction. IQVIA brings roughly 93,000 employees and relationships with 19 of the top 20 pharmaceutical companies. Komodo brings a more concentrated AI-native architecture and a 330-million-patient data foundation. The two approaches represent competing bets on how this workforce transformation resolves: does AI integration happen inside the incumbent's massive services machine, or inside a purpose-built platform company that starts with AI as its core operating system?

The distinction matters for hiring. IQVIA's model layers AI agents on top of an existing global workforce that spans clinical research, commercial analytics, and healthcare intelligence. Its AI hiring, reflected in roles like SVP of Applied AI Science and VP of Machine Learning, tends to sit inside a large corporate structure where AI expertise must coexist with deep regulatory and operational knowledge. Komodo's model builds AI into the product and data layer from the start, which means its open roles skew toward engineers and AI specialists who can work directly on the Marmot platform. The Director of Procurement role and the Manager, Consulting positions in India suggest the company is also building the operational backbone to support enterprise-scale client delivery, not just product development.

Other major incumbents in life sciences intelligence have taken a more measured approach to AI integration, focusing on augmenting existing data and analytics portfolios rather than rebuilding around an agentic architecture. Neither has published detailed workforce composition data that isolates AI-native roles from traditional services positions, making direct comparison difficult. What is clear is that the market category itself is shifting: Deloitte's 2025 RWE benchmark survey found that biopharma companies increasingly rely on real-world evidence and expect generative AI to play a transformative role, even as they struggle to measure the return on that investment.

That tension, between AI ambition and ROI proof, is where Komodo's bet gets interesting. If the Marmot platform can demonstrably compress the time from clinical question to actionable insight in RNAi drug development, it creates a template that other therapeutic areas will want to replicate. Each new partnership becomes a workforce proof point: more AI engineers, more healthcare data scientists, more hybrid roles that did not exist two years ago. The Alnylam expansion is one data point. The next one will tell whether this model scales beyond a single high-profile RNAi collaboration into something that actually restructures how biopharma hires.

Working in frontier tech? Zero G Talent tracks the openings: browse frontier tech jobs, openings at Komodo Health, and the people building the field.